TURNING THE TIDE: BRAF-TARGETED THERAPY ENABLING SURGICAL DOWNSTAGING IN STAGE IVC ANAPLASTIC THYROID CANCER
Abstract
Introduction: Anaplastic thyroid cancer (ATC) constitutes less than 2% of thyroid cancer but accounts for up to 50% of thyroid cancer mortality, with a median survival of 3–6 months. All ATC is Stage IV at diagnosis by definition. BRAF V600E-mutant disease is the only molecularly defined subset with FDA-approved targeted therapy (dabrafenib–trametinib). We report a case in which BRAF-directed therapy enabled curative-intent surgery in a patient with Stage IVC disease. Case Report: A 68-year-old woman presented with a rapidly enlarging right thyroid mass, facial plethora and internal jugular vein thrombosis. Core biopsy and immunohistochemistry confirmed ATC; next-generation sequencing revealed a BRAF V600E, TERT promoter and TP53 “triple-hit” signature arising from a dedifferentiated papillary carcinoma. PET-CT showed an FDG-avid primary, nodal disease and bilateral lung metastases (Stage IVC). She received palliative external beam radiotherapy and chemotherapy, followed by dabrafenib plus trametinib, achieving a 70% partial response with resolution of nodal and pulmonary disease. Disease progression eight months later prompted addition of pembrolizumab, complicated by immune-related granulomatous panniculitis requiring discontinuation. Multidisciplinary review subsequently confirmed an isolated thyroid remnant with no residual nodal or distant disease, permitting total thyroidectomy with bilateral neck dissection. Results and Conclusion: Histopathology confirmed unifocal ATC with 40% treatment response, a 1 mm ancestral papillary carcinoma focus, and involved margins; disease was restaged as ypT3bN1a (Stage IVA). The patient is euthyroid on levothyroxine, receiving adjuvant radiotherapy, with BRAF-targeted therapy to resume thereafter with three-monthly surveillance imaging. This case shows that BRAF-directed dual MAPK blockade can downstage unresectable, metastatic ATC to resectable disease, transforming outcomes in a malignancy once regarded as fatal. Early BRAF testing and multidisciplinary care are essential to enable this therapeutic paradigm shift.
Related
- A Granular Interaction Framework for Surgical Robotic Digital Twins: Enabling Realistic Segment-Level Manipulation in Extended Reality
- Post-transplant oncologic outcomes after locoregional downstaging before living donor liver transplantation for hepatocellular carcinoma beyond Milan criteria: a systematic review and meta-analysis of selected cohorts
- From cN2 to ypN0: Nodal Downstaging After Neoadjuvant Treatment in Breast Cancer—A Retrospective Cohort Study from a Tertiary Cancer Center
- Bilateral breast implant-associated anaplastic large cell lymphoma presenting as late peri-implant effusion: a case report
- Statement of Retraction: Long noncoding RNA MALAT1 knockdown inhibits progression of anaplastic thyroid carcinoma by regulating miR-200a-3p/FOXA1.
BibTeX
@article{francis2026turning,
title = {{TURNING THE TIDE: BRAF-TARGETED THERAPY ENABLING SURGICAL DOWNSTAGING IN STAGE IVC ANAPLASTIC THYROID CANCER}},
author = {Floris Ann Francis and Naveen Shivappa Kannur and Vijay Pillai and Nidhi Tandon and Saurabha Kumar and Nisheena Raghavan and Subramanian Kannan},
journal = {Thyroid Research \& Practice},
year = {2026},
month = oct,
doi = {10.4103/trp.trp_50_26},
url = {https://doi.org/10.4103/trp.trp_50_26},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - TURNING THE TIDE: BRAF-TARGETED THERAPY ENABLING SURGICAL DOWNSTAGING IN STAGE IVC ANAPLASTIC THYROID CANCER
AU - Floris Ann Francis
AU - Naveen Shivappa Kannur
AU - Vijay Pillai
AU - Nidhi Tandon
AU - Saurabha Kumar
AU - Nisheena Raghavan
AU - Subramanian Kannan
PY - 2026
DA - 2026/10/01
JO - Thyroid Research & Practice
DO - 10.4103/trp.trp_50_26
UR - https://doi.org/10.4103/trp.trp_50_26
AB - Introduction: Anaplastic thyroid cancer (ATC) constitutes less than 2% of thyroid cancer but accounts for up to 50% of thyroid cancer mortality, with a median survival of 3–6 months. All ATC is Stage IV at diagnosis by definition. BRAF V600E-mutant disease is the only molecularly defined subset with FDA-approved targeted therapy (dabrafenib–trametinib). We report a case in which BRAF-directed therapy enabled curative-intent surgery in a patient with Stage IVC disease. Case Report: A 68-year-old woman presented with a rapidly enlarging right thyroid mass, facial plethora and internal jugular vein thrombosis. Core biopsy and immunohistochemistry confirmed ATC; next-generation sequencing revealed a BRAF V600E, TERT promoter and TP53 “triple-hit” signature arising from a dedifferentiated papillary carcinoma. PET-CT showed an FDG-avid primary, nodal disease and bilateral lung metastases (Stage IVC). She received palliative external beam radiotherapy and chemotherapy, followed by dabrafenib plus trametinib, achieving a 70% partial response with resolution of nodal and pulmonary disease. Disease progression eight months later prompted addition of pembrolizumab, complicated by immune-related granulomatous panniculitis requiring discontinuation. Multidisciplinary review subsequently confirmed an isolated thyroid remnant with no residual nodal or distant disease, permitting total thyroidectomy with bilateral neck dissection. Results and Conclusion: Histopathology confirmed unifocal ATC with 40% treatment response, a 1 mm ancestral papillary carcinoma focus, and involved margins; disease was restaged as ypT3bN1a (Stage IVA). The patient is euthyroid on levothyroxine, receiving adjuvant radiotherapy, with BRAF-targeted therapy to resume thereafter with three-monthly surveillance imaging. This case shows that BRAF-directed dual MAPK blockade can downstage unresectable, metastatic ATC to resectable disease, transforming outcomes in a malignancy once regarded as fatal. Early BRAF testing and multidisciplinary care are essential to enable this therapeutic paradigm shift.
SN - 0973-0354
SN - 2250-1452
ER -